OLT1177 is a selective and orally active NLRP3 inflammasome inhibitor which reverses the metabolic cost of inflammation. In vitro, nanomolar concentrations of OLT1177 reduced IL-1β and IL-18 release following canonical and noncanonical NLRP3 inflammasome activation. The molecule showed no effect on the NLRC4 and AIM2 inflammasomes, suggesting specificity for NLRP3.

KEYWORDS: OLT1177 | Supplier | NLRP3 inhibitor | Dapansutrile | OLT 1177 | OLT-1177 | CAS [54863-37-5] | NF-κB Pathway | NOD1 | Inhibitor | Receptors | Autoimmune encephalomyelitis | Cryopyrin